IDO1 and melanoma: In preclinical models, a dual inhibitor of topoisomerase II and IDO1 [148]—a drug conjugate of D-1MT, an IDO inhibitor and paclitaxel [149], and a drug conjugate of D-1MT and gallic acid (GA-1MT) [150]—were described to have potent antiproliferative activity against melanoma cells.